<DOC>
	<DOCNO>NCT01654016</DOCNO>
	<brief_summary>Aim study : To investigate difference expression inflammatory marker venous wall blood among patient treat Detralex treat Detralex ( control group ) .</brief_summary>
	<brief_title>Study Antiinflammatory Effects Detralex ( Daflon )</brief_title>
	<detailed_description>Chronic venous disease ( CVD ) represent one common vascular disorder . It 's different clinical manifestation ( often see varicose vein ) observe 40 % adult female population 30 % adult male . Different mechanical biological factor play role process deterioration venous wall tone consequent vein valve disfunction eventually lead increase venous pressure . Evidence suggest inflammation central place process even early stage CVD . Usual symptoms venous insufficiency pain , leg heaviness , night cramping , itching , often accompany leg edema . The extent clinical manifestation may correlate patient ' symptom . Treatment varicose vein encompass vein surgery ( strip , phlebectomy , radiofrequency laser ablation ) , sclerotherapy compression therapy . Detralex ( country register Daflon ) oral flavonoid consist 90 % micronized diosmin 10 % flavonoid express hesperidin . Several study show beneficial effect Detralex alleviate symptom patient CVD . It may use conjunction surgery , sclerotherapy , compression therapy may therapy therapeutical modality indicate feasable . Animal study show antiinflammatory effect Daflon way Daflon act favorably microcirculatory complication normalize synthesis prostaglandin free radical . It decrease bradykinin-induced microvascular leakage inhibits leukocyte activation , trap , migration . However , search available literature ( MEDLINE ) find study investigated antiinflammatory effect flavonoid human . The aim study investigate difference expression inflammatory marker venous wall blood patient treat Detralex treat Detralex ( control group ) .</detailed_description>
	<mesh_term>Venous Insufficiency</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>Chronic venous disease ( CEAP 2 3 ) saphenofemoral insufficiency Previous deep venous thrombosis Previous acute thrombophlebitis GSV ( confirm duplex finding morphologic change GSV knee ) Immunological disorder Diabetes type I II , Severe inflammatory disease : Behcet , lupus , Horton arteritis , polyarthritis , spondylarthritis sclerodermia Recent ( less 3 month ) schedule nonauthorized nonpharmacological treatment : Sclerotherapy , Surgical treatment varicose vein ( crossectomy , phlebectomy ) , Endovenous treatment ( endovenous laser , radiofrequency ) , Nonauthorized pharmacological treatment last 3 month study : Antiinflammatory agent ( except acetylsalicylic acid dose 350 mg daily ) , Systemic corticosteroids immunosuppressive , Venoactive drug include open label MPFF , Pentoxifylline Patients already ( time randomization ) take Detralex symptom link chronic venous disease Arterial insufficiency ( absent pedal pulse ABI &lt; 0.9 ) Any important clinical laboratory abnormality Pregnancy , breastfeed wish become pregnant study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>varicose vein</keyword>
	<keyword>inflammation</keyword>
</DOC>